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metrial ablation, low intensity pulsed ultrasound (LIPUS) and negative pressure
wound therapy were investigated further, through interviews with country and
product experts. RESULTS: Hospital and ambulatory sales could not be separated
but some differences in total sales between countries were apparent. Where HTA
processes existed they appeared to slow down access to new technologies. Several
interviewees highlighted a lack of expertise on local purchasing groups where
decisions are often based upon in-year budget considerations which restrict access
to some cost effective technologies. Even where new technologies are found to be
cost effective, DRG based funding systems are insufficiently flexible to establish
new out-patient fee levels. Hospitals have no financial incentive to treat patients in
an out-patient setting if the procedure cost exceeds existing out-patient DRG fees.
This prevents innovative technologies from being used in the most appropriate
way and cost saving opportunities are missed. CONCLUSIONS: Health providers
need to demonstrate new technologies are cost effective before commissioners
agree funding outside DRG based fee systems. The negotiation process would be
more efficient if commissioners pooled expertise for reviewing cost-effectiveness
evidence and fed their conclusions directly to DRG code and Tariff setting author-
ities. New DRG codes and higher out-patient tariffs for cost effective technologies
that enable a switch to ambulatory care could incentivise hospitals to revise care
pathways. Benefits will include lower procedure costs than in-patient treatment or
improved outcomes for patients.
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A SURVEY OF “JOINT WORKING” BETWEEN THE PHARMACEUTICAL INDUSTRY
AND THE NATIONAL HEALTH SERVICE IN THE UK
Lockwood C1, Marinoni G1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK
OBJECTIVES: An increasingly high-profile policy initiative being driven by the De-
partment of Health (DoH), the Association of the British Pharmaceutical Industry
(ABPI) and National Health Service (NHS) stakeholders, “joint working” encom-
passes a variety of forms of collaboration between the industry and the NHS in the
UK (UK). This study sought to characterise the current landscape for joint working
in the UK by surveying the types of projects being undertaken by participants.
METHODS: Secondary research was conducted to establish a comprehensive list of
joint-working projects; the websites of major pharmaceutical companies, the ABPI,
the DoH and other NHS stakeholders were surveyed for any references to joint
working. A classification system was created to segment projects by type of
scheme, therapeutic area(s) and stakeholders involved. This segmentation was
analysed to look for qualitative trends in the UK joint-working environment.
RESULTS: A key finding of the study is that many pharmaceutical companies are
now active in joint working. Joint-working projects encompass a broad range of
therapeutic areas, with most companies active in areas in which they have assets.
These projects can be segmented into a number of different categories, including
those centered on service (re)design, service appraisals in light of current guide-
lines, and techniques to better manage or educate patients. Pharmaceutical com-
panies are also active in providing training or other types of support to health care
professionals and managers within the NHS. CONCLUSIONS: The joint-working
policy initiative in the UK has resulted in a significant number of partnerships
within the NHS in recent years. These projects are varied in nature, and have seen
the pharmaceutical industry and the health service cooperate in innovative ways.
Increasingly, companies are willing to share their expertise and resources in proj-
ects which have indirect benefits for them in terms of the market access of their
products.
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DRUG PRICING IN BOSNIA AND HERZEGOVINA
Catic T, Begovic B
ISPOR Bosnia and Herzegovina Regional Chapter, Sarajevo, Bosnia
OBJECTIVES: To compare and explain current drug pricing systems in Bosnia and
Herzegovina (B&H) for reimbursed drugs by Health Insurance Funds (HIF) and out-
of-pocket drugs. METHODS: Analysis of reimbursement list and legislation on ac-
ces to drugs in B&H is performed. We analysed pricing for reimbursed drugs and
out-of-pocket drug prices regulation and explain cost structure. RESULTS: General
drug pricing system is set by Agency for medicines and medical devices of B&H.
Prices are defined as maximal wholeseler price (WSP) and pricing is based on re-
feral pricing. Referal countries are Croatia, Serbia, Slovenia, Austria and Italy. B&H
price must be set at level of referal price with addoption for patented drug (100%),
originator (95%) and generics (90%). Prices are revised each year and published on
Agency website. Maximal wholeseler margine is up to 8%, while retail margine is
set by entity laws. In Federation maximal retail margine is 25% while in Republic of
Srpska margine is fixed on 20% add on WSP. Reimbursable price in Republic of
Srpska is defined as lowest offered price for each INN and presentation. Price dif-
ference can be paid by patient depenting on preferences. Reimbursed prices for
drugs included into Federal reimbursement list is set by nagotiation process with
manufacturers. All prices should be revised and adopted annualy to the Agency
published prices. Retail margine is not applicable for reimbursed drugs because
pharmacy is paid by HIF per prescription according to the agreement.
CONCLUSIONS: Even there is intention to unify pharmaceutical market and drug
prices in Bosnia and Herzegovine, there are still differences in price and related
pricing regulations. Recently published Rule on price control by state Agency
should contribute to equalisation of prices in Bosnia and Herzegovina.
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THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE
AVERAGE TURNOVER OF COMMUNITY PHARMACIES BETWEEN 2007-2010
Boncz I1, Donka-Verebes É2, Oberfrank F3
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Experimental Medicine (IEM)., Budapest, Hungary
OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the annual turnover of community pharmacies. METHODS: Data were derived
from the pharmaceutical database of the Hungarian Health Insurance Fund Ad-
ministration (OEP), the only health care financing agency in Hungary. We analysed
the 5 years period between 2006-2010. The main indicator of our analyses was the
annual turnover of pharmacies calculated on health insurance reimbursement
according to the number of population of different settlements. RESULTS: The
average annual turnover – calculated on health insurance reimbursement – of a
community pharmacy was 176.8 million Hungarian Forint (HUF) or 669011 EUR in
2006 with significant differences according to the size of population. Pharmacies
located in small cities had a much lower average annual turnover (0-499 popula-
tion: 105.6 million HUF; 500-999: 41.9 million HUF; 1000-1999: 63.2 million HUF),
while the turnover of pharmacies located in bigger cities, was significantly higher
(10000-49999 population: 217.6 million HUF; 50000-99999: 231.9 million HUF; over
100000: 241.6 million HUF). The average annual turnover of a community pharmacy
was 135.4 million Hungarian Forint (HUF) or 491627 EUR in 2010, i.e. 76.6 % of 2006’s
turnover. Between 2006 and 2010, the annual turnover of pharmacies in small
villages (population 0-1999) varied between 86.1-103.7 % while those of big cities
(population over 10000) changed to 66.9-76.5 %. CONCLUSIONS: The annual turn-
over of pharmacies in small villages was significantly lower than those of big towns
during the study period 2006-2010. However, the annual turnover of small villages’
pharmacies decreased moderately compared to pharmacies located in bigger
towns because new pharmacies were established in bigger towns.
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AVAILABILITY AND PRICING OF INNOVATIVE PHARMACEUTICALS IN THE TOP
5 EUROPEAN PHARMACEUTICAL MARKETS
Reinaud F1, Ando G2
1IHS, Paris, France, 2IHS Global Insight, London, UK
OBJECTIVES: In an attempt to assess time to market and price levels of innovative
drugs, we surveyed market availability and drug prices for a basket of drugs in the
top 5 European pharmaceutical markets.METHODS: The market availability of 125
innovative drugs – approved between July 2009 and April 2012 by the European
Medicines Agency – in France, Germany, Italy, Spain, and the United-Kingdom was
analysed. Within this sample, prices of 10 drugs marketed in each of the market
studied were compared. RESULTS: Most of the drugs included in our sample are
marketed in Germany and the UK, 59% and 54% respectively. In Spain, France and
Italy this figure drops to 39%, 33%, and 32% respectively. It should be highlighted
that only 14% of the drugs was available in all the markets analysed. Prices are
commonly the highest in Germany and lower in Italy or the UK. Additionally, while
for an identical drug, most examples show significant price differences between
the markets studied, a few showed that the price corridor was relatively narrow.
CONCLUSIONS:Our results show that Germany and the UK – where prices have not
been directly controlled – are still prioritised, while market entry occurs at a later
stage in France, Italy and Spain. The fact that large price differences are still ob-
served between countries means that there is still flexibility in terms of pricing
strategies. The pricing procedure implemented in 2011 in Germany, has not had an
immediate impact on prices - which are still the highest. However, an impact is
already being felt on market access. Several innovative drugs were not launched in
Germany when the price outcome was expected to be unsuccessful.
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PATENTED DRUG EXTENSION STRATEGIES ON HEALTH CARE SPENDING: A
COST-EVALUATION ANALYSIS
Vernaz N1, Haller G1, Girardin F1, Huttner B1, Dayer P1, Muscionico D2, Salomon JL2,
Bonnabry P1
1University of Geneva Hospitals, Geneva, Switzerland, 2OFAC, Geneva, Switzerland
OBJECTIVES: Drug manufacturers, facing patent protection termination, have de-
veloped strategies to maintain market share. These include marketing evergreen-
ing drugs (slow release formulations, single isomer chiral molecules, or structural
analogues/combinations of original patented drugs) and offering high rebates to
hospitals that use brand-name or evergreening drugs. Our objective was to assess
the financial impact of evergreening drug prescriptions in the community, and to
measure the impact of a hospital restrictive drug formulary (RDF) on health care
expenditures. METHODS: We combined three administrative registries from the
canton of Geneva, Switzerland to analyse all prescriptions between January 2000
and December 2008. We developed cost-minimisation models calculating ever-
greening and brand drug prescriptions at their corresponding generic selling price
equivalents. ARIMA models measured the spillover effect of hospital prescription
patterns into the community. Spillover costs were compared to hospital savings.
Summary results were aggregated on a yearly basis and extrapolated to the canton
of Geneva. RESULTS: Evergreening drug prescriptions resulted in an extra cost of
€20,172,000 over the study period. Brand drug extra costs decreased from €6,555,000
(2004) to €1,403,000 (2008), but were offset by the increase in evergreening drug
prescriptions (“squeezing the balloon” phenomenon). The final extra cost to the
health care system was €42,147,000. The use of a hospital RDF to control cost
resulted in global savings of €837,000. However, listing drugs on the hospital RDF
decreased health care system savings to €31,000 only due to increased prescription
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use in the community (spillover effect). CONCLUSIONS: Evergreening drugs suc-
cessfully compete with generics, offsetting cost containment strategies including
generic medication substitution or a hospital RDF, particularly so if hospitals in-
clude evergreening or brand drugs on their RDF. For effectiveness, prescriptions
should be coordinated at the state level rather than from a payer perspective, or
hospitals should implement strategies to systematically switch patients to generic
drugs at discharge.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the number of pharmacies.METHODS:Data were derived from the pharmaceu-
tical database of the Hungarian Health Insurance Fund Administration (OEP), the
only health care financing agency in Hungary. We analysed the 5 years period
between 2006-2010. The number of pharmacies were analysed according to the
number of population of different settlements. RESULTS: The number of commu-
nity pharmacies increased from 2030 (2006) to 2576 (2010) by 546 pieces (26.9 %).
The number of pharmacies showed a different pattern according to the size of
population of settlements. In villages with a population of 0-449, 500-999 and 1000-
1999, the number of pharmacies decreased (3 pieces / 3.6 %; 18 pieces / 20.0 %; 23
pieces / 10.6 % respectively). In cities with a population between 2000-4999 we
found a slight increase in the number of pharmacies (11 pieces / 3.0 %). In bigger
towns there was a clear increase in the number of pharmacies: 5000-9999 popula-
tion 53 pieces / 29.0 %; 10000-49999 194 pieces / 37.1 %; 50000-99999 population 129
pieces / 33.0 % and over the population of 100000: 158 pieces / 42.9 %.
CONCLUSIONS: After the introduction of the new law for the economical use of
medications in 2006, the number of pharmacies significantly changed in Hungary.
However, this change in the number of pharmacies was inequal according to the
size of the population: in villages with a population lower than 2000 people there
was a decrease, while in cities with bigger population the number of pharmacies
significantly increased.
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2010-2012 GLOBAL HEALTH CARE REFORMS AND THEIR IMPACT ON PRICING,
ACCESS AND HEALTH OUTCOMES STRATEGY
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: During 2009-2012 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the United
States, AMNOG in Germany, HSPT in France, KVG in Switzerland, Ustawa Refun-
dacyjna in Poland and NHS proposed reform in the UK. These reforms have major
implications on pricing, market access and HEOR strategy for drug and device
products. METHODS: To understand the implications of these trends, we analyzed
2009-2012 reform bills and proposed changes worldwide. Additionally, we inter-
viewed public and private payers, key opinion leaders and payer-influencers to
understand implications of these reforms on drug and device manufacturers.
Stakeholders ranked various data collection methods on a scale of 1-10 (1-least
important and 10-most important). RESULTS: The global health care landscape is
expected to undergo significant change during 2012-2016. In the United States,
government will play increased role as a single payer, especially with?Medicare,
Medicaid and CHIP programs? which will cover 114 million Americans, at a cost of
$784 billion. In Germany, AMNOG bill marked the end of free drug pricing and
would lead to increased insurance premiums (now 15.5% of wages). In the UK, NHS
has proposed to replace PCTs with 500-1000 GP-led consortia and use value-based
pricing for expensive drugs and devices. Randomized controlled trial, budget im-
pact model and systematic reviews —ranked highest (7.5-9.1) among payers. Over-
all, payers view that in the future, health economic assessments would play critical
role in pricing, coverage and reimbursement of branded products. CONCLUSIONS:
This analysis shows that global health care landscape is expected to undergo sig-
nificant change during 2012-2016. Discussions with payers, KOLs and payer-influ-
encers highlights increased importance of HEOR data in the future.
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THE IMPACT OF ORPHAN DRUG INCENTIVES ON INNOVATION AND PRICING IN
NICHE THERAPEUTIC MARKETS: A SYSTEMATIC REVIEW OF THE LITERATURE
Kapur AK
Boston Healthcare Associates, Inc., Boston, MA, USA
OBJECTIVES: To review the impact orphan drug (OD) legislation has had on inno-
vation and pricing of therapeutic products for rare diseases in the US, EU, and
Japan. METHODS: A systematic literature review was conducted, seeking English-
language studies published after the enactment of initial OD legislation in 1983.
EMBASE, Medline, and Business Source Complete were searched and results
screened for studies specifically assessing the impact of industry-focused policy
interventions using 1) measurable innovation- and pricing-related outcomes, and
2) specifying appropriate comparators. In addition to being abstracted for informa-
tion on research setting, counterfactuals, outcomes, and findings, the methodolog-
ical quality of included studies was evaluated with an adapted tool. RESULTS:
Twenty unique studies met the inclusion criteria: 14 discussing innovation out-
comes and 7 discussing pricing outcomes. Increasingly strong study designs have
been used to validate that that OD legislation has increased cross-market approv-
als and suggest the increasing role of small biotechnology companies. Select re-
search also shows a positive relationship between disease prevalence and the
likelihood of indicated ODs and is bolstered by well-controlled regression-continu-
ity studies showing sustained innovation in higher prevalence OD markets. How-
ever, some concerns are raised regarding innovation in low prevalence conditions
and conditions just above OD thresholds. Pricing studies were almost exclusively
focused on the EU. A multiple-regression analysis demonstrated that merely hav-
ing an OD designation leads to a higher price, with 4 weaker studies suggesting an
inverse relationship between rare disease prevalence and acquisition price.
CONCLUSIONS: Despite an abundance of opinion and case study pieces in OD
literature, specific studies of high internal validity exist, as do defined and usable
comparator group classifications. The reviewed studies ought to serve as valuable
information for policymakers considering policy extensions for ultra-orphans, in-
ternational markets, or other niche therapeutic areas, as well as demonstration of
best-practices in designing well-controlled studies evaluating biopharmaceutical
policies.
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GENERIC DRUG MARKET ACCESS IN JAPAN
Yoshida E1, Toumi M2
1Creativ-Ceutical Ltd, London, UK, 2University Claude Bernard Lyon 1, Lyon, France
The Japanese generic drug market is not well developed. The generic volume share
is 20% of the total market vs. 74% and 64% in the USA and UK. The slow uptake of
generics is often explained by the “Brand Lover” profile of Japan. No formal review
of drug policy has been undertaken to understand the slow uptake of generics.
OBJECTIVES: To review the current Japanese drug policy regarding generic drugs
and to appreciate the incentive and disincentive to use generic. METHODS: We
reviewed the current Japanese generic drug policy enacted by the Ministry of
Health, Labour and Welfare (MHLW), and the Japanese Generic Medicines Associ-
ation’s website. RESULTS: Major policies to enhance generic uptake were issued in
2002, 2006 and 2010. They required that prescriptions specify if substitution gener-
ics are acceptable, and provide some modest financial incentives for pharmacies
and hospitals to substitute only with the patient’s agreement. In 2012, INN pre-
scription is encouraged but not requested. The recent introduction of Japanese DRG
hospital funding, and the 2011 Japan-India Economic Partnership Agreement,
which opened the Japanese market to Indian generic drug manufacturers, are ex-
pected to boost the generic market. However, small pricing gaps between generic
and branded drugs, the lack of mandatory substitution and INN prescription, little
price discounting and little education towards the public might explain the slow
uptake of generics in Japan, relative to the West. CONCLUSIONS: Although the
“Brand Lover” assumption is candidly used to explain the lack of traction by generic
drugs, this review finds the lack of policy incentives to boost generic adoption,
better explain current levels of generics penetration. Shall the authorities be will-
ing to encourage generic uptake more effective policy incentive are needed.
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ROLE OF SUBGROUP ANALYSES FOR TECHNOLOGY ASSESSMENT AND
COVERAGE DECISIONS
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Cost effectiveness analyses play a critical role in determining cover-
age of novel drugs and devices. Increasingly, payers are demanding subgroup anal-
yses to determine indications which would be covered by the national health sys-
tem or insurance agency. METHODS: To understand and review trends in use of
subgroup cost effectiveness analysis, we analyzed NICE HTAs for products ap-
proved in 2011-2012. Manufacturer submissions for CEA were compared to final
review and decision by HTA agency. Analogs were identified and case studies were
developed to further understand the use of subgroup analyses and cost effective-
ness models. RESULTS: Decisions made by NICE in 2011-2012 show increasing
trends towards the use of subgroup analysis for determining indications for cov-
erage by national payer bodies. During 2011-2012, 80% of the assessments included
subgroup analyses. Approximately half of them included cost effectiveness anal-
yses for various subgroups. Interestingly, the ICER values estimated by NICE for the
same subgroups showed a large variation (1X-3X fold difference) compared to ICER
values estimated by manufacturers. Selected case studies highlighted that for sev-
eral products NICE is recommending treatments only for subgroups whose ICER
values are within the cost effectiveness threshold. CONCLUSIONS: New products
need robust broader population and subgroup analyses for insurance coverage.
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THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE
CATCHMENT POPULATION OF COMMUNITY PHARMACIES BETWEEN 2007-2010
Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of
Experimental Medicine (IEM)., Budapest, Hungary
OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the catchment population of community pharmacies. METHODS: Data were
derived from the pharmaceutical database of the Hungarian Health Insurance
Fund Administration (OEP), the only health care financing agency in Hungary. We
analysed the 5 years period between 2006-2010. The main indicator of our analyses
is the average population of one pharmacy (catchment population) in the counties
of Hungary. RESULTS: The average catchment population of a pharmacy was 4933
inhabitants (( 592, standard deviation, SD) in 2006, while in 2010 it decreased to
3.888 ( 450) inhabitants per pharmacy. We found the largest catchment popula-
A291V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
